Neuroprotection

3

Review clinical trials related to Neuroprotection. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma

This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial. This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence. The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function. The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.

Participants needed: 108
Trial details
Age: 50-75Biological sex: AllType: InterventionalSponsor: Institut Catala de RetinaUpdated: Jan 14, 2026Locations: 2
Eligibility criteria

At least 4 reliable visual field (VF) tests before study enrollment. [+2]

Use of any vitamin or nutraceutical supplement in the month prior to screening. [+3]

Status: Recruiting

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)

To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Hui-Sheng ChenUpdated: Aug 21, 2025Locations: 1
Eligibility criteria

Age ≥18 years; [+4]

Modified Rankin Score >2 caused by a history of prior stroke; [+5]

Status: Recruiting

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

Neurodevelopmental impairment due to delayed brain development and brain injury is a fundamental problem in children with critical congenital heart disease (CCHD). Significant longterm motor-, cognitive-, and behavioral problems are the result of early postnatally and perioperatively induced brain injury. Allopurinol, a xanthine oxidase inhibitor, prevents the formation of toxic free oxygen radicals, thereby limiting hypoxia-reperfusion damage. Both animal and neonatal studies suggest that administration of allopurinol reduces hypoxic-ischemic brain injury, is cardioprotective, and safe. This study aims to evaluate the efficacy and safety of allopurinol administered early postnatally and perioperatively in children with a CCHD requiring cardiac surgery with cardiopulmonary bypass.

Participants needed: 236
Trial details
Phase: Phase 3Age: Up to 1Biological sex: AllType: InterventionalSponsor: dr. M.J.N.L. BendersUpdated: May 16, 2024Locations: 4
Eligibility criteria

Neonates with a prenatally or postnatally confirmed diagnosis of CCHD requiring... [+1]

Inability to enroll the patient before the start of delivery in case of prenatal... [+4]